This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Imaging			
Radiolabeled anti-prostate-specific antigen (KLK3; PSA) antibody for prostate cancer diagnostics	<p>A radiolabeled anti-PSA antibody could help image bone metastases and determine response to prostate cancer therapy. To enable prostate tumor-specific imaging, an antibody targeting free PSA (fPSA), a form of PSA unbound by serum proteins, was radiolabeled with ^{89}Zr. In a PET study of prostate cancer xenograft mice, the antibody detected a decrease in fPSA levels in the xenograft after treatment with the anti-androgen receptor small molecule MDV3100 compared with after treatment using vehicle. In mice, the antibody detected xenograft prostate cancer lesions injected into bone but did not detect lesions caused by mechanical bone injury. Next steps include humanizing the antibody and conducting clinical testing in 2013.</p> <p>MDV3100, a triple-acting oral anti-androgen receptor from Medivation Inc. and Astellas Pharma Inc., is in Phase III testing to treat castration-resistant prostate cancer (CRPC). Corresponding author Charles Sawyers is a co-inventor of MDV3100.</p> <p>SciBX 5(18); doi:10.1038/scibx.2012.482 Published online May 3, 2012</p>	Patent and licensing status undisclosed	<p>Ulmert, D. <i>et al. Cancer Discov.</i>; published online March 31, 2012; doi:10.1158/2159-8290.CD-11-0316</p> <p>Contact: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: sawyersc@mskcc.org</p> <p>Contact: Jason S. Lewis, same affiliation as above e-mail: lewisj2@mskcc.org</p> <p>Contact: Hans Lilja, same affiliation as above e-mail: liljah@mskcc.org</p>